The FDA just approved a new depression treatment—and it doesn’t involve medication

The Food and Drug Administration approved a new depression treatment device in December that uses mild electrical currents to stimulate the brain, marking a potential shift away from medication-centric approaches. This technology, known as transcranial direct-current stimulation (tDCS), is designed for at-home use and is intended to offer a more accessible alternative to traditional therapies, according to The New York Times. The approval specifically applies to a headset developed by Flow Neuroscience, a Swedish company that has been researching this method for years. While tDCS technology has been available for over two decades and in use in England since 2019, the FDA's decision grants it significant legitimacy in the United States, where similar devices had previously been relegated to the wellness product market. Anna Wexler, an assistant professor of medical ethics at the University of Pennsylvania, stated that the approval legitimizes tDCS as a medical therapy rather than just an online wellness product. The device functions by delivering a low electrical current to the brain, which lowers the neuronal firing threshold and may enhance communication between brain regions. This mechanism aligns with a growing scientific understanding of depression as a disorder involving disrupted neural connectivity, moving beyond the sole focus on chemical imbalances. For decades, treatments like selective serotonin reuptake inhibitors (SSRIs), which gained prominence in the late 1980s, have been the primary approach, with approximately one in six Americans currently taking an antidepressant. Experts like Mark George from the Medical University of South Carolina suggest that devices like tDCS could help psychiatry evolve beyond its current reliance on pharmaceuticals.